---
figid: PMC9139943__cancers-14-02504-g004
figtitle: 'Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms
  and Clues to Overcome Resistance'
organisms:
- Homo sapiens
- Mus musculus
pmcid: PMC9139943
filename: cancers-14-02504-g004.jpg
figlink: /pmc/articles/PMC9139943/figure/cancers-14-02504-f004/
number: F4
caption: In this figure, PARPis and anti-VEGF/VEGFRi cooperate to induce HRD. The
  hypoxia-inducible factor (HIF1) increases VEGF expression, which interacts with
  neuropilins (NRPs), and VEGF/NRP signaling promotes homologous recombination (HR)
  through the Hippo pathway transducers YAP/TAZ, which activate the RAD51 promoter
  via the transcription factor TEAD. In contrast, hypoxia inhibits RAD51 via transcriptional
  repressor E2F4/p130 or inhibits BRCA1 by epigenetic silencing, leading to impaired
  HR. Thus, hypoxia exhibits contradictory actions, inhibition, or activation of HR.
  In this context, anti-VEGF agents or VEGFR inhibitors (VEGFRis) suppress VEGF/NRP
  signaling, causing impaired HR, whereas PARPis inhibit BRCA1 and RAD51 expression
  via increased formation of the transcriptional repressor E2F4/p130, resulting in
  enhanced HRD. Thus, PARPis and anti-VEGF/VEGFRi can cooperate to elicit the HRD
  phenotype to achieve additive or synergistic effects.
papertitle: 'Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms
  and Clues to Overcome Resistance.'
reftext: Satoru Kyo, et al. Cancers (Basel). 2022 May;14(10):2504.
year: '2022'
doi: 10.3390/cancers14102504
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: ovarian cancer | PARP inhibitor | maintenance therapy | homologous recombination
  deficiency | replication fork | DNA damage response | cGAS/STING | cytosolic immunity
automl_pathway: 0.9598259
figid_alias: PMC9139943__F4
figtype: Figure
organisms_ner:
- Homo sapiens
- Mus musculus
redirect_from: /figures/PMC9139943__F4
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9139943__cancers-14-02504-g004.html
  '@type': Dataset
  description: In this figure, PARPis and anti-VEGF/VEGFRi cooperate to induce HRD.
    The hypoxia-inducible factor (HIF1) increases VEGF expression, which interacts
    with neuropilins (NRPs), and VEGF/NRP signaling promotes homologous recombination
    (HR) through the Hippo pathway transducers YAP/TAZ, which activate the RAD51 promoter
    via the transcription factor TEAD. In contrast, hypoxia inhibits RAD51 via transcriptional
    repressor E2F4/p130 or inhibits BRCA1 by epigenetic silencing, leading to impaired
    HR. Thus, hypoxia exhibits contradictory actions, inhibition, or activation of
    HR. In this context, anti-VEGF agents or VEGFR inhibitors (VEGFRis) suppress VEGF/NRP
    signaling, causing impaired HR, whereas PARPis inhibit BRCA1 and RAD51 expression
    via increased formation of the transcriptional repressor E2F4/p130, resulting
    in enhanced HRD. Thus, PARPis and anti-VEGF/VEGFRi can cooperate to elicit the
    HRD phenotype to achieve additive or synergistic effects.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRCA1
  - RBL2
  - NOLC1
  - RAB3GAP1
  - E2F4
  - RAD51
  - HIF1A
  - SETD2
  - ARNT
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - TAFAZZIN
  - WWTR1
  - YAP1
  - TEAD1
  - TEAD2
  - TEAD3
  - TEAD4
  - Brca1
  - Rbl2
  - Nolc1
  - Rab3gap1
  - E2f4
  - Rad51
  - Xrcc2
  - Vegfa
  - Tafazzin
  - Wwtr1
  - Yap1
---
